Drug discovery

Introducing Quantinuum: The World's Largest Integrated Quantum Computing Company

Tuesday, November 30, 2021 - 7:57pm

CAMBRIDGE, England and BROOMFIELD, Colo., Nov. 30, 2021 /PRNewswire/ -- The two leading companies in the quantum computing industry have combined to create Quantinuum, thereby accelerating the development of quantum computing and innovation of quantum technologies in a platform agnostic manner to deliver real-world quantum-enabled solutions for some of the most intractable problems that classical computers have not been able to solve.

Key Points: 
  • "Quantinuum is now the largest and most advanced integrated quantum computing company in the world," said Ilyas Khan, CEO of the new company and founder of Cambridge Quantum.
  • "I am thrilled to help lead our new company, which will positively change the world through the application of quantum computing.
  • Quantinuum was formed six months after Honeywell announced that Honeywell Quantum Solutions, its quantum computing division, would separate from the company and combine with Cambridge Quantum.
  • Honeywell will initially be the largest shareholder of Quantinuum with an approximately 54 percent ownership stake in the new company.

Introducing Quantinuum: The World's Largest Integrated Quantum Computing Company

Tuesday, November 30, 2021 - 7:52pm

CAMBRIDGE, England and BROOMFIELD, Colo., Nov. 30, 2021 /PRNewswire/ -- The two leading companies in the quantum computing industry have combined to create Quantinuum, thereby accelerating the development of quantum computing and innovation of quantum technologies in a platform agnostic manner to deliver real-world quantum-enabled solutions for some of the most intractable problems that classical computers have not been able to solve.

Key Points: 
  • "Quantinuum is now the largest and most advanced integrated quantum computing company in the world," said Ilyas Khan, CEO of the new company and founder of Cambridge Quantum.
  • "I am thrilled to help lead our new company, which will positively change the world through the application of quantum computing.
  • Quantinuum was formed six months after Honeywell announced that Honeywell Quantum Solutions, its quantum computing division, would separate from the company and combine with Cambridge Quantum.
  • Honeywell will initially be the largest shareholder of Quantinuum with an approximately 54 percent ownership stake in the new company.

Honeywell Quantum Solutions And Cambridge Quantum Complete Business Combination To Form World's Largest, Most Advanced Standalone Quantum Company

Tuesday, November 30, 2021 - 5:30pm

CHARLOTTE, N.C., Nov. 30, 2021 /PRNewswire/ --Honeywell (NASDAQ: HON) announced today that Honeywell Quantum Solutions (HQS) and Cambridge Quantum (CQ), two global leaders in quantum computing and technology, received regulatory approval and completed the previously announced business combination.

Key Points: 
  • CHARLOTTE, N.C., Nov. 30, 2021 /PRNewswire/ --Honeywell (NASDAQ: HON) announced today that Honeywell Quantum Solutions (HQS) and Cambridge Quantum (CQ), two global leaders in quantum computing and technology, received regulatory approval and completed the previously announced business combination.
  • The new company, named Quantinuum, is now the largest and most advanced full-stack quantum computing company.
  • "The formation of Quantinuum marks an important milestone for the quantum computing industry," said Darius Adamczyk, chairman and chief executive officer of Honeywell, and chairman of Quantinuum.
  • The combination of the quantum industry's top talent, growing customer base, and most comprehensive technology will position Quantinuum extremely well for future growth."

Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit Dispensary of Hope

Tuesday, November 30, 2021 - 3:00pm

Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, TN.

Key Points: 
  • Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, TN.
  • The group chose Dispensary of Hope because of the strong representation of innovation and improved health outcomes in the pharmaceutical industry.
  • We are pleased to support Dispensary of Hope in their efforts to address this need," said Shawn O'Connor, Chief Executive Officer of Simulations Plus.
  • Dispensary of Hope is committed to providing access to high quality medication for America's most vulnerable (low income and uninsured) with dignity.

ORION ANNOUNCES THE RAPID LEAD OPTIMIZATION OF OB-004 - A CCR2 ANTAGONIST

Tuesday, November 30, 2021 - 3:07pm

OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor.

Key Points: 
  • OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor.
  • Using its proprietary drug discovery technology, Orion successfully completed the development of OB-004 from target identification to lead optimization in only 6 months, a significant reduction in discovery time compared to industry averages.
  • Furthermore, based on inhibition of in vitro signaling, OB-004 is a best-in-class CCR2 antagonist compared to other small molecule CCR2 antagonists in development.
  • Development of a best-in-class CCR2 antagonist in 6 months is an extraordinary accomplishment and validates the power and versatility of our drug discovery platform said Dr. Oliver Hartley, Vice President of Drug Discovery at Orion Biotechnology.

Global Proteomics Research Report 2021: Markets, Technologies, and Competitive Landscape Analysis & Forecasts 2020-2024 & 2030 - ResearchAndMarkets.com

Tuesday, November 30, 2021 - 2:15pm

Markets for proteomic technologies are analyzed for the year 2020 and are projected to years 2024 and 2030.

Key Points: 
  • Markets for proteomic technologies are analyzed for the year 2020 and are projected to years 2024 and 2030.
  • The most commonly used technologies are 2D gel electrophoresis for protein separation and analysis of proteins by mass spectrometry.
  • the evaluation of protein expression for the understanding of toxic events, is an important application of proteomics in preclinical drug safety.
  • Proteomics will play an important role in the medicine of the future which will be personalized and will combine diagnostics with therapeutics.

Parks Associates: Adoption of Connected Medical Devices has Increased to 25% of US Broadband Households in 2021

Tuesday, November 30, 2021 - 2:15pm

The research firm reports that 55% of US broadband households now own a connected health device , while adoption of connected medical devices, which includes smart thermometers, connected blood-pressure cuffs, and wireless CPAP machines, increased from 15% in 2020 to 25% in 2021.

Key Points: 
  • The research firm reports that 55% of US broadband households now own a connected health device , while adoption of connected medical devices, which includes smart thermometers, connected blood-pressure cuffs, and wireless CPAP machines, increased from 15% in 2020 to 25% in 2021.
  • "Consumers recognize value in the ability to share data from their devices or apps," said Kristen Hanich , Sr. Analyst, Parks Associates.
  • "Interoperability is critical for extending the value of connected devices and services in remote patient care."
  • Connected Health Summit: Consumer Engagement and Innovation is a virtual executive conference focused on the impact of connected devices and IoT healthcare solutions on consumers at home.

Padma Kodukula Joins A-Alpha Bio as Chief Business Officer

Tuesday, November 30, 2021 - 2:00pm

SEATTLE, Nov. 30, 2021 /PRNewswire-PRWeb/ --A-Alpha Bio, a biotechnology company improving human health by unlocking the potential of protein-protein interactions, today announced that Padma Kodukula, industry expert in platform technologies, has joined the company as Chief Business Officer.

Key Points: 
  • SEATTLE, Nov. 30, 2021 /PRNewswire-PRWeb/ --A-Alpha Bio, a biotechnology company improving human health by unlocking the potential of protein-protein interactions, today announced that Padma Kodukula, industry expert in platform technologies, has joined the company as Chief Business Officer.
  • "Padma brings an invaluable combination of subject-matter expertise and leadership experience to A-Alpha Bio," said David Younger, CEO of A-Alpha Bio.
  • We're proud to welcome Padma, and I look forward to closely working alongside her as we aggressively expand our business."
  • As Chief Business Officer, Kodukula will be responsible for developing and executing A-Alpha Bio's overall corporate and business strategy.

23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer

Tuesday, November 30, 2021 - 2:15pm

SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the companys new Chief Scientific Officer.

Key Points: 
  • SUNNYVALE, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and therapeutics company, today announced the appointment of Joseph R. Arron, M.D., Ph.D., as the companys new Chief Scientific Officer.
  • We are excited to have Joe join as our Chief Scientific Officer, as he brings a proven track record of innovation in drug discovery and translational biology to 23andMe, said Hillan.
  • Dr. Arron will lead 23andMes therapeutics discovery strategy from early discovery to the IND-enabling studies stage.
  • 23andMe is trying to make this vision a reality, and I hope to help carry forward the companys mission.

Global Biochips/Microarray Markets, Technologies, & Competitive Landscape Analysis & Forecasts, 2021-2025 & 2030 with 2020 as the Base Year - ResearchAndMarkets.com

Tuesday, November 30, 2021 - 1:02pm

This report is an analysis of biochip/microarray markets based on technologies and applications.

Key Points: 
  • This report is an analysis of biochip/microarray markets based on technologies and applications.
  • The report starts with a description of technologies as a basis for the estimation of markets.
  • Technologies include array comparative genomic hybridization (CGH), copy number variation (CNV), DNA methylation, ChIP-Chip, RNA splice variants, and microRNA.
  • The share of microarray technologies in other areas will grow with the maximum growth in RNA splice variants followed by epigenetics.